Compare EXPO & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | CPRX |
|---|---|---|
| Founded | 1967 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 1996 | 2006 |
| Metric | EXPO | CPRX |
|---|---|---|
| Price | $67.65 | $23.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $90.50 | $35.00 |
| AVG Volume (30 Days) | 461.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | ★ 2.07 | 1.68 |
| Revenue | ★ $582,014,000.00 | $119,072,803.00 |
| Revenue This Year | $12.61 | $8.00 |
| Revenue Next Year | $8.00 | $9.77 |
| P/E Ratio | $33.60 | ★ $13.91 |
| Revenue Growth | 4.21 | ★ 16.39 |
| 52 Week Low | $63.81 | $19.05 |
| 52 Week High | $84.00 | $26.56 |
| Indicator | EXPO | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 41.69 |
| Support Level | $64.70 | $22.46 |
| Resistance Level | $73.22 | $24.86 |
| Average True Range (ATR) | 2.21 | 0.97 |
| MACD | -0.36 | -0.11 |
| Stochastic Oscillator | 9.87 | 28.16 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.